Last reviewed · How we verify
conventional IP antibiotics
Conventional IP antibiotics inhibit bacterial protein synthesis or cell wall integrity through established mechanisms, thereby killing or stopping the growth of susceptible bacteria.
Conventional IP antibiotics inhibit bacterial protein synthesis or cell wall integrity through established mechanisms, thereby killing or stopping the growth of susceptible bacteria. Used for Bacterial infections (broad spectrum depending on specific antibiotic class and susceptibility).
At a glance
| Generic name | conventional IP antibiotics |
|---|---|
| Sponsor | Alice Ho Miu Ling Nethersole Hospital |
| Drug class | Antibiotic (conventional/established classes) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
IP antibiotics refer to a broad category of conventional antimicrobial agents that have been in clinical use for decades. These drugs typically work through well-characterized mechanisms such as inhibition of bacterial ribosomal protein synthesis (e.g., aminoglycosides, tetracyclines, macrolides), disruption of bacterial cell wall synthesis (e.g., beta-lactams), or inhibition of nucleic acid synthesis. The specific mechanism depends on the antibiotic class within this conventional portfolio.
Approved indications
- Bacterial infections (broad spectrum depending on specific antibiotic class and susceptibility)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, vomiting)
- Allergic reactions (rash, urticaria)
- Photosensitivity (with certain classes)
- Ototoxicity (with aminoglycosides)
- Nephrotoxicity (with aminoglycosides)
Key clinical trials
- Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional IP antibiotics CI brief — competitive landscape report
- conventional IP antibiotics updates RSS · CI watch RSS
- Alice Ho Miu Ling Nethersole Hospital portfolio CI